intellectual vanities… about close to everything

Unnoticed Mutation In AIDS Virus Can Cause Drug Resistance

with 2 comments

A mutation in a little-studied structural region of the AIDS virus can cause resistance to several HIV drugs, according to a study published in PLoS Medicine by Gilda Tachedjian and colleagues from Australia, Canada, and the United States.

jun06_resistance1.jpg

Several mutations in reverse transcriptase (RT), the viral enzyme that copies the genes of HIV, are already known to cause drug resistance and are routinely detected in blood tests used by physicians to individualize HIV treatment. The mutation in this study, designated N348I, is located not in the active part of RT, but rather in the so-called connection domain, which falls outside the region of the virus normally included in resistance tests.

The researchers analyzed the first two-thirds of the RT gene in viruses isolated from more than 1,000 patients in Canada, and found that virus carrying the N348I mutation developed in more than 10% of treatment-experienced patients. Patients treated with the HIV drugs zidovudine and nevirapine were 2.6-times more likely to have the N348I mutation than patients not treated with these drugs.

The mutation appeared early in therapy, often in viruses that had other resistance mutations. Furthermore, the appearance of the N348I mutation often coincided with an increase in the amount of HIV present in blood. When the researchers introduced the N348I mutation into HIV growing in the laboratory, they found that it decreased the susceptibility of the virus to drugs.

Because the N348I mutation confers resistance to two classes of RT inhibitor drugs and can emerge early during therapy, it could have a large impact on patient responses to antiviral regimens that contain zidovudine and nevirapine. It might now be worth investigating whether looking for the N348I mutation (and for other mutations outside the region of RT included in current tests) could improve the ability of resistance tests to predict treatment outcomes.

Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, et al. (2007)

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance.

PLoS Med 4(12): e335 doi:10.1371/journal.pmed.0040335

Background

The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H) domains. Almost all known RT inhibitor resistance mutations identified to date map to the polymerase domain of the enzyme. However, the connection and RNase H domains are not routinely analysed in clinical samples and none of the genotyping assays available for patient management sequence the entire RT coding region. The British Columbia Centre for Excellence in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective statistical analyses of the Centre’s database have identified an N348I mutation in the RT connection domain in treatment-experienced individuals. The objective of this multidisciplinary study was to establish the in vivo relevance of this mutation and its role in drug resistance.

Methods and Findings

The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective drug pressure, and its association with changes in viral load, specific drug treatment, and known drug resistance mutations was analysed from genotypes, viral loads, and treatment histories from the Centre’s database. N348I increased in prevalence from below 1% in 368 treatment-naïve individuals to 12.1% in 1,009 treatment-experienced patients (p = 7.7 × 10−12). N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p < 0.001), the lamivudine resistance mutations M184V/I (p < 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p < 0.001). The association with TAMs and NNRTI resistance mutations was consistent with the selection of N348I in patients treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95% confidence interval 1.43–4.81). The appearance of N348I was associated with a significant increase in viral load (p < 0.001), which was as large as the viral load increases observed for any of the TAMs. However, this analysis did not account for the simultaneous selection of other RT or protease inhibitor resistance mutations on viral load. To delineate the role of this mutation in RT inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different genetic backbones. N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wild-type HIV-1 or when combined with TAMs. N348I also decreased susceptibility to nevirapine (7.4-fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when combined with K103N. Biochemical analyses of recombinant RT containing N348I provide supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give some insight into the molecular mechanism of resistance.

Conclusions

This study provides the first in vivo evidence that treatment with RT inhibitors can select a mutation (i.e., N348I) outside the polymerase domain of the HIV-1 RT that confers dual-class resistance. Its emergence, which can happen early during therapy, may significantly impact on a patient’s response to antiretroviral therapies containing zidovudine and nevirapine. This study also provides compelling evidence for investigating the role of other mutations in the connection and RNase H domains in virological failure.

Written by huehueteotl

December 3, 2007 at 11:53 am

2 Responses

Subscribe to comments with RSS.

  1. have you never read Peter Duesberg?

    olen

    December 3, 2007 at 10:23 pm

  2. science is so tiresome. we’re all gonna die.

    olen

    December 3, 2007 at 10:23 pm


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: